STERIS (STE) Stock Forecast & Price Target

Steris is supported by a durable healthcare franchise that delivered FQ1-27 revenue of $1,493M, 6.2% constant-currency organic growth, with Healthcare Services still running at DD levels for 14 consecutive quarters and segment margins expanding 60bp to 24.8%. Management’s FY'27 outlook for 6-7% constant-currency revenue growth and adj. EPS of $11.10-$11.30 looks credible because AST volumes are expected to accelerate, HC equipment orders rose 8% with backlog at 3-year highs, and life sciences remained strong. The company also posted EPS of $2.59, beat on gross margin at 46.0%, kept gross leverage near 1.2x, and has capital allocation flexibility through bolt-on acquisitions and a $1B buyback program.

Steris is highly exposed to weaker global healthcare spending, since lower procedure volumes would directly pressure its predominantly Healthcare Services revenue base and could slow demand across its sterilization and infection-prevention platform. Its outlook is further clouded by tariff policy changes and new FDA regulatory actions, both of which could raise costs, disrupt operations, or force compliance-related spending at a time when supply chain and inflationary pressures are already squeezing margins. In addition, the company faces lumpiness in capital equipment purchases, making revenue and cash flow less predictable across its sterilizers, washer-disinfectors, and other decontamination businesses.